Issue 41, 2023

An industrially applicable Escherichia coli platform for bioconversion of thebaine to oripavine and codeine to morphine

Abstract

A whole cell Escherichia coli biotransformation platform converting thebaine to oripavine and codeine to morphine was demonstrated with industrially applicable yields (∼1.2 × 10−2 g L−1 h−1 or ∼1.2 × 10−1 g L−1 h−1), improving >13 400-fold upon morphine production in yeast. Mutations enhanced enzyme performance and the use of a purified substrate with rich raw poppy extract expanded applicability.

Graphical abstract: An industrially applicable Escherichia coli platform for bioconversion of thebaine to oripavine and codeine to morphine

Supplementary files

Article information

Article type
Communication
Submitted
06 Feb 2023
Accepted
24 Apr 2023
First published
27 Apr 2023

Chem. Commun., 2023,59, 6251-6254

An industrially applicable Escherichia coli platform for bioconversion of thebaine to oripavine and codeine to morphine

G. W. K. Spencer, X. Li, A. Jarrold and S. L. Gras, Chem. Commun., 2023, 59, 6251 DOI: 10.1039/D3CC00534H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements